Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0296 | 0.6031 | 0.5 |
Mycobacterium leprae | Probable fructose bisphosphate aldolase Fba | 0.0145 | 0.2093 | 0.5 |
Echinococcus granulosus | fructose 16 bisphosphatase 1 | 0.011221 | 0.5 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0296 | 0.6031 | 0.5 |
Leishmania major | 0.011221 | 0.5 | 0.5 | |
Toxoplasma gondii | fructose-bisphospatase II | 0.011221 | 0.5 | 0.5 |
Echinococcus multilocularis | fructose 1,6 bisphosphatase 1 | 0.011221 | 0.5 | 0.5 |
Brugia malayi | fructose-1,6-bisphosphatase | 0.011221 | 0.5 | 0.5 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0152 | 0.2287 | 0.5 |
Onchocerca volvulus | 0.0449 | 1 | 0.5 | |
Giardia lamblia | Fructose-bisphosphate aldolase | 0.0296 | 0.6031 | 0.5 |
Loa Loa (eye worm) | fructose-1,6-bisphosphatase | 0.011221 | 0.5 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0296 | 0.6031 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0296 | 0.6031 | 0.5 |
Loa Loa (eye worm) | fructose-1,6-bisphosphatase | 0.0152 | 0.2287 | 0.2287 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0152 | 0.2287 | 0.5 |
Schistosoma mansoni | fructose-16-bisphosphatase-related | 0.011221 | 0.5 | 0.5 |
Echinococcus multilocularis | fructose 1,6 bisphosphatase 1 | 0.0152 | 0.2287 | 1 |
Toxoplasma gondii | fructose-bisphospatase II | 0.0152 | 0.2287 | 0.5 |
Leishmania major | 0.0152 | 0.2287 | 0.5 | |
Treponema pallidum | fructose-bisphosphate aldolase | 0.0296 | 0.6031 | 0.5 |
Entamoeba histolytica | fructose-1,6-bisphosphate aldolase, putative | 0.0296 | 0.6031 | 0.5 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.011221 | 0.5 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0296 | 0.6031 | 0.5 |
Mycobacterium tuberculosis | Probable fructose-bisphosphate aldolase Fba | 0.0145 | 0.2093 | 0.5 |
Entamoeba histolytica | fructose-1,6-bisphosphate aldolase, putative | 0.0296 | 0.6031 | 0.5 |
Trypanosoma brucei | fructose-1,6-bisphosphatase | 0.011221 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0449 | 1 | 1 |
Brugia malayi | fructose-1,6-bisphosphatase | 0.0152 | 0.2287 | 0.2287 |
Mycobacterium ulcerans | fructose-bisphosphate aldolase | 0.0145 | 0.2093 | 0.5 |
Echinococcus granulosus | fructose 16 bisphosphatase 1 | 0.0152 | 0.2287 | 1 |
Trypanosoma brucei | fructose-1,6-bisphosphatase | 0.0152 | 0.2287 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0296 | 0.6031 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0449 | 1 | 1 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0296 | 0.6031 | 0.5 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.011221 | 0.5 | 0.5 |
Schistosoma mansoni | fructose-16-bisphosphatase-related | 0.0152 | 0.2287 | 1 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0296 | 0.6031 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 0.005 uM | Antimalarial activity against chloroquine and pyrimethamine resistant Plasmodium falciparum K1 | ChEMBL. | 24900219 |
Inhibition (functional) | = 3.3 % | Antimalarial activity against Plasmodium berghei NK-65 infected in ICR mouse assessed as inhibition of parasitemia at 100 mg/kg, po administered as single dose on day 1 measured on day 4 | ChEMBL. | 24900219 |
MSD (functional) | = 6.3 day | Antimalarial activity against Plasmodium berghei NK-65 infected in ICR mouse assessed as survival days at 100 mg/kg, po administered as single dose (Rvb = 6 days) | ChEMBL. | 24900219 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | 24900219 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.